Source: Contract Pharma

Crescendo Biologics: Crescendo Biologics Secures $32M to Expand CB307 Trial

Expansion cohort underway in individuals with PSMA+ metastatic castration-resistant prostate cancer.

Read full article »
Crescendo Biologics's Competitors | Crescendo Biologics's News | Crescendo Biologics's Financials
Stay up-to-date with the latest news on Crescendo Biologics
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Theodora Harold's photo - CEO of Crescendo Biologics

CEO

Theodora Harold

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Crescendo Biologics